The main activities of the "PharmaDiall" company are search, development, chemical synthesis, "in vitro" and "in vivo" testing, organization and performing the clinical trials (all phases) and patenting of new biologically active chemicals that can later turn into drugs.

As part of this work, the drug "Dimolegin" was developed - an anticoagulant belonging to the class of the direct oral inhibitors of the blood coagulation system factor Xa. Anticoagulants are a class of drugs that prevent the formation of blood clots. There are several classes of anticoagulants. The class of direct oral anticoagulants is considered the best for most indications. Indications for use are the prevention and treatment of thrombosis in the postoperative period – this is about a month's course, as well as a lifetime appointment for atrial fibrillation and the risk of repeated strokes, heart attacks. In addition, doctors often prescribe these drugs for indications not included in the recommended list - "off label". For example, cancer patients, high–risk pregnancies, during IVF. Also, "off label" these drugs are recommended for patients diagnosed with COVID-19.

Dimolegin is currently the first original anticoagulant in the world, which, according to the results of a phase 3 clinical trial, showed higher efficacy compared to the comparison drug Kleksan (the closest in terms of indications of use to COVID symptoms from the temporary recommendations of the Ministry of Health of the Russian Federation). In addition, in phase 2 clinical trials, higher efficacy of Dimolegin (at a dose of 60 mg / day) was demonstrated, compared with Fragmin (dalteparin sodium) as a means of preventing venous thrombosis in patients undergoing knee replacement, while the safety indicator is the frequency of cumulative large and clinically significant small bleeding was low.

The results obtained for the developed drug "Dimolegin" are unique for the entire recent history of pharmaceuticals in the Russian Federation.


  • it has unique pharmacokinetic parameters, because of which it has the potential to be the best drug in the class in terms of the ratio of potential benefit to risk of use;
  • according to the convenience of use (once a day), it contributes to a better adherence of patients to therapy and the outcome of treatment;
  • a potential blockbuster on the market, the international volume of which is at least 30 billion US $ / year, and the Russian in 2021 – 61.5 billion rubles, such a drug will undoubtedly be in demand on the market.